Koh Bong Y
CIK 0001615979 Name as filed on the most recent filing
Filed as Koh Bong Y (50)
124 transaction lines · from 50 filings · filed 2014-08-07 to 2026-03-27 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER KalVista Pharmaceuticals, Inc. 15 filings
- ISSUER Oruka Therapeutics, Inc. 2 filings
- ISSUER Tricida, Inc. 20 filings
- ISSUER VistaGen Therapeutics, Inc. 1 filings
- ISSUER Unum Therapeutics Inc. 1 filings
- ISSUER Altimmune, Inc. 2 filings
- ISSUER Constellation Pharmaceuticals Inc 1 filings
- ISSUER Bellerophon Therapeutics, Inc. 6 filings
- ISSUER AveXis, Inc. 1 filings
- ISSUER Avalanche Biotechnologies, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
1 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-26 |
KalVista Pharmaceuticals, Inc. KALV |
S, Open-market sale | 21,386 disposed | 17.76 | 379,815.36 | Form 4, filing 0001231919-26-000286 | |
| 2026-03-26 |
KalVista Pharmaceuticals, Inc. KALV |
S, Open-market sale | 15,417 disposed | 18.82 | 290,147.94 | Form 4, filing 0001231919-26-000286 | |
| 2026-03-26 |
KalVista Pharmaceuticals, Inc. KALV |
S, Open-market sale | 3,183 disposed | 19.12 | 60,858.96 | Form 4, filing 0001231919-26-000286 | |
| 2026-03-25 |
KalVista Pharmaceuticals, Inc. KALV |
S, Open-market sale | 174,485 disposed | 16.95 | 2,957,520.75 | Form 4, filing 0001231919-26-000286 | |
| 2026-03-25 |
KalVista Pharmaceuticals, Inc. KALV |
S, Open-market sale | 160 disposed | 17.53 | 2,804.80 | Form 4, filing 0001231919-26-000286 | |
| 2025-04-09 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 25,000 acquired | 9.42 | 235,500.00 | Form 4, filing 0001415889-25-010587 | |
| 2025-02-14 |
Oruka Therapeutics, Inc. ORKA |
P, Open-market purchase | 88,794 acquired | 11.44 | 1,015,803.36 | Form 4, filing 0001415889-25-005908 | |
| 2025-02-13 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 61,700 acquired | 9.33 | 575,661.00 | Form 4, filing 0001415889-25-004324 | |
| 2025-02-13 |
Oruka Therapeutics, Inc. ORKA |
P, Open-market purchase | 14,950 acquired | 11.63 | 173,868.50 | Form 4, filing 0001415889-25-005908 | |
| 2025-02-12 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 100,000 acquired | 9.23 | 923,000.00 | Form 4, filing 0001415889-25-004324 | |
| 2025-02-12 |
Oruka Therapeutics, Inc. ORKA |
P, Open-market purchase | 8,971 acquired | 11.86 | 106,396.06 | Form 4, filing 0001415889-25-005908 | |
| 2025-02-11 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 26,703 acquired | 9.18 | 245,133.54 | Form 4, filing 0001415889-25-003665 | |
| 2025-02-11 |
Oruka Therapeutics, Inc. ORKA |
P, Open-market purchase | 9,593 acquired | 10.95 | 105,043.35 | Form 4, filing 0001415889-25-005908 | |
| 2025-02-10 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 4,137 acquired | 9.14 | 37,812.18 | Form 4, filing 0001415889-25-003665 | |
| 2025-02-10 |
Oruka Therapeutics, Inc. ORKA |
P, Open-market purchase | 574 acquired | 10.90 | 6,256.60 | Form 4, filing 0001415889-25-005908 | |
| 2025-02-07 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 73,649 acquired | 9.29 | 684,199.21 | Form 4, filing 0001415889-25-003665 | |
| 2025-02-03 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 14,562 acquired | 9.22 | 134,261.64 | Form 4, filing 0001415889-25-002809 | |
| 2025-01-31 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 11,754 acquired | 8.89 | 104,493.06 | Form 4, filing 0001415889-25-002809 | |
| 2025-01-30 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 43,707 acquired | 8.76 | 382,873.32 | Form 4, filing 0001415889-25-002809 | |
| 2024-02-08 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 29,747 acquired | 14.70 | 437,280.90 | Form 4, filing 0001415889-24-003118 | |
| 2024-02-07 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 51,827 acquired | 14.56 | 754,601.12 | Form 4, filing 0001415889-24-003118 | |
| 2024-02-06 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 4,474 acquired | 14.74 | 65,946.76 | Form 4, filing 0001415889-24-003118 | |
| 2024-01-30 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 88,099 acquired | 14.47 | 1,274,792.53 | Form 4, filing 0001415889-24-002183 | |
| 2024-01-29 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 80,600 acquired | 14.22 | 1,146,132.00 | Form 4, filing 0001415889-24-001941 | |
| 2024-01-26 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 4,174 acquired | 12.98 | 54,178.52 | Form 4, filing 0001415889-24-001941 | |
| 2024-01-25 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 7,030 acquired | 12.73 | 89,491.90 | Form 4, filing 0001415889-24-001941 | |
| 2024-01-24 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 20,686 acquired | 12.44 | 257,333.84 | Form 4, filing 0001415889-24-001781 | |
| 2024-01-23 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 10,897 acquired | 12.54 | 136,648.38 | Form 4, filing 0001415889-24-001781 | |
| 2024-01-22 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 67,546 acquired | 12.55 | 847,702.30 | Form 4, filing 0001415889-24-001781 | |
| 2024-01-19 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 25,000 acquired | 12.43 | 310,750.00 | Form 4, filing 0001209191-24-001957 | |
| 2024-01-18 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 39,680 acquired | 12.51 | 496,396.80 | Form 4, filing 0001209191-24-001957 | |
| 2024-01-17 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 78,925 acquired | 12.60 | 994,455.00 | Form 4, filing 0001209191-24-001957 | |
| 2024-01-16 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 19,599 acquired | 12.73 | 249,495.27 | Form 4, filing 0001209191-24-001666 | |
| 2024-01-11 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 6,647 acquired | 12.68 | 84,283.96 | Form 4, filing 0001209191-24-001666 | |
| 2024-01-10 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 47,700 acquired | 12.67 | 604,359.00 | Form 4, filing 0001209191-24-001403 | |
| 2024-01-09 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 20,816 acquired | 12.56 | 261,448.96 | Form 4, filing 0001209191-24-001403 | |
| 2024-01-08 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 69,184 acquired | 12.44 | 860,648.96 | Form 4, filing 0001209191-24-001403 | |
| 2024-01-04 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 41,764 acquired | 12.11 | 505,762.04 | Form 4, filing 0001209191-24-001008 | |
| 2024-01-03 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 17,605 acquired | 12.20 | 214,781.00 | Form 4, filing 0001209191-24-001008 | |
| 2023-12-29 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 6,013 acquired | 12.49 | 75,102.37 | Form 4, filing 0001209191-23-060015 | |
| 2023-12-28 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 471,490 acquired | 12.50 | 5,893,625.00 | Form 4, filing 0001209191-23-060015 | |
| 2023-12-27 |
KalVista Pharmaceuticals, Inc. KALV |
P, Open-market purchase | 41,514 acquired | 11.97 | 496,922.58 | Form 4, filing 0001209191-23-060015 | |
| 2022-10-26 |
Tricida, Inc. TCDA |
S, Open-market sale | 2,367,174 disposed | 0.46 | 1,088,900.04 | Form 4, filing 0001209191-22-054671 | |
| 2022-10-25 |
Tricida, Inc. TCDA |
S, Open-market sale | 1,970,418 disposed | 0.57 | 1,123,138.26 | Form 4, filing 0001209191-22-054671 | |
| 2022-10-24 |
Tricida, Inc. TCDA |
S, Open-market sale | 2,113,948 disposed | 0.61 | 1,289,508.28 | Form 4, filing 0001209191-22-054671 | |
| 2022-10-19 |
Tricida, Inc. TCDA |
P, Open-market purchase | 241,366 acquired | 10.29 | 2,483,656.14 | Form 4, filing 0001209191-22-054201 | |
| 2022-10-19 |
Tricida, Inc. TCDA |
P, Open-market purchase | 70,100 acquired | 11.25 | 788,625.00 | Form 4, filing 0001209191-22-054201 | |
| 2022-10-18 |
Tricida, Inc. TCDA |
P, Open-market purchase | 40,400 acquired | 11.98 | 483,992.00 | Form 4, filing 0001209191-22-054201 | |
| 2022-10-17 |
Tricida, Inc. TCDA |
P, Open-market purchase | 170,292 acquired | 11.67 | 1,987,307.64 | Form 4, filing 0001209191-22-053863 | |
| 2022-10-13 |
Tricida, Inc. TCDA |
P, Open-market purchase | 4,674 acquired | 11.98 | 55,994.52 | Form 4, filing 0001209191-22-053863 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.
- Open-market purchase 1
- Open-market sale 0
- Option exercise 0
- Grant or award 0
- Tax withholding 0
- Disposition to the issuer 0
- In-the-money option exercise 0
How to cite this page
ebomi catalog. Koh Bong Y, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001615979
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6